Stimulant overdose deaths continue to rise, even as opioid overdoses decline—and there are still no FDA-approved medications to treat stimulant use disorder (StUD). The most effective approach, contingency management (CM), uses tangible rewards to encourage abstinence, but its long-term impact on outcomes like mortality remains unclear. This study in the American Journal of Psychiatry explores whether patients with StUD who receive CM have a reduced risk of death.

Full study: https://psychiatryonline.org/doi/10.1176/appi.ajp.20250053?asam.org